Levonat Adverse Reactions

Infections and invasions: mycoses (and proliferation of other resistant microorganisms).
Blood and lymphatic system disorders: leucopenia, eosinophilia, thrombocytopenia, neutropenia, agranulocytosis, pancytopenia, hemolytic anemia.
Immune system disorders: anaphylactic shock (see Precautions), anaphylactic and anaphylactoid reactions may sometimes appear after the first dose administration, increased sensitivity (hypersensitivity) (see Precautions).
Metabolic and nutrition disorders: anorexia, hypoglycemia, especially in patients with diabetes (see Precautions).
Mental disorders: insomnia, nervousness, psychotic disorders, depression, confused consciousness, anxiety, agitation, alarm, psychotic reactions with self-destructive behavior, including suicidal ideation or action (see Precautions), hallucinations.
Nervous system disorders: dizziness, headache, drowsiness. Rare: convulsions, tremor, paresthesia, sensor or sensomotor peripheral neuropathy, disgeusia (subjective taste disorder), including ageusia (loss of the sense of taste), parasomia (smell disorder), including anosmia (absence of the sense of smell).
Sight disorders: visual disturbances.
Hearing and ear labyrinth disorders: vertigo, acoustic disturbance, tinnitus.
Heart disorders: tachycardia, prolongation of the QT interval on the electrocardiogram (see prolongation of the QT interval under Precautions and Overdosage).
Vascular disorders: hypotension.
Respiratory, thoracic and mediastinal disorders: bronchial spasms, dyspnea, allergic pneumonitis.
Gastrointestinal disorders: diarrhea, nausea, vomiting, abdominal pains, dyspepsia, abdominal distention, constipation, hemorrhagic diarrhea, which in rare cases may indicate enterocolitis, including pseudomembranous colitis.
Hepatobiliary disorder: increased liver enzyme levels (ALT, AST, alkaline phosphatase, gamma-glutaminetransferase). Infrequent: increased blood serum bilirubin, hepatitis, cases of jaundice and heavy liver injury, including cases of acute liver insufficiency have been reported during levofloxacin administration, predominantly in patients with heavy main diseases (see Precautions).
Skin side effects and general hypersensitivity reactions: rash, itching, urticaria, angioneurotic edema, hypersensitivity to sunlight and ultraviolet emission, toxic epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome, exudative multiform erythema, hyperhidrosis. Sometimes skin and mucosal reactions may occur after the first dose administration.
Bone, muscle and connective tissues disorders: tendon injury, (see Precautions), including their inflammations (tendinitis) (for example tendinitis of Achilles tendon), arthralgia, myalgia, tendon rupture (see Dosage & Administration). This side effect may appear within 48 hours from the beginning of treatment and impact the Achilles tendon of both legs. Muscular weakness, which may be significant for patients with myasthenia gravis, muscle damage (rhabdomyolysis) are possible.
Kidneys and urinary system disorders: increased level of creatinine in blood serum, acute renal insufficiency (for example, coursed by interstitial nephritis).
Systemic disorders and conditions in the place of drug administration: pain and redness in the place of infusion; phlebitis, asthenia, pyrexia, pain (including pain in a back, chest and limb pain). Among other side effects, associated with fluoroquinolone administration, are the following: extrapyramidal symptoms and other disturbance of movements coordination; hypersensitive vasculitis; attacks of porphyria in patients with porphyria.